Connecticut is currently home to 1244 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study
NCT05612594
Recruiting
The goal of this clinical trial is to test if bexagliflozin lowers the sleep apnea severity in adults who are overweight or obese with moderate to severe obstructive sleep apnea (OSA) compared with a placebo (look-alike substance that contains no active drug). The main question it aims to answer is: * If SGLT2i will reduce anatomic and physiologic traits, clinical measures of OSA and sleep deficiency in participants * If improvement in clinical measures are because of improvement in the anatom... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/04/2024
Locations: Yale New Haven Health, New Haven, Connecticut
Conditions: Sleep Apnea
Register for Updates
Regulating Blood Pressure During Recovery from Intracerebral Hemorrhage and Ischemic Stroke
NCT04760717
Recruiting
The purpose of this research study is to determine whether blood pressure treatment regimens with spironolactone are better than blood pressure treatment regimens without spironolactone at lowering blood pressure in stroke survivors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/30/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Intracerebral Hemorrhage, Spironolactone, Ischemic Stroke
Register for Updates
Assessing the Efficacy of an Acceptance-Based Digital Intervention for Veterans With Chronic Pain
NCT06058624
Recruiting
Pain has been identified as among the most frequent presenting medical complaints, in particular within primary care for Veterans. There are few areas of daily living and functioning that pain intensity does not impact, with reported pain intensity related to difficulties in social situations and changes in activities of daily life, sleep, and appetite. Therapeutic interventions such as Acceptance and Commitment Therapy for Chronic Pain (ACT-CP) that target issues related to the cognitions and e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/28/2024
Locations: VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut
Conditions: Chronic Pain
Register for Updates
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
NCT05378672
Recruiting
This research study will investigate whether dasiglucagon as a rescue therapy for participants under 6 years of age works and is safe to use. In addition, the study will investigate how dasiglucagon works in the body (pharmacokinetics and pharmacodynamics). Participants will receive 1 single dose as an injection under the skin (subcutaneous, s.c.) into the buttocks. Participants will have 3 visits with the study team. For each participant, the study will last up to 84 days.
Gender:
ALL
Ages:
5 years and below
Trial Updated:
08/27/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Hypoglycemia, Type 1 Diabetes
Register for Updates
CLOZAPINE Response in Biotype-1
NCT04580134
Recruiting
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
08/27/2024
Locations: Hartford Healthcare, Hartford, Connecticut
Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Register for Updates
Intradermal Influenza Vaccination
NCT06067555
Recruiting
The goal of this study is to characterize the immune response, both innate and adaptive, as well as locally and systemic, to intradermal (ID) vaccination in healthy individuals. The intervention involves intradermal administration of an FDA-approved intramuscular seasonal influenza vaccine, using an FDA-approved device MicronJet. Investigators will measure antibody titers, cell subtypes, and multi-omic profiles, by collecting skin and peripheral blood at baseline and at several time points after... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
08/26/2024
Locations: Church Street Research Unit, New Haven, Connecticut
Conditions: Vaccine Reaction
Register for Updates
Post Market Registry Study of the Philips QuickClear Mechanical Thrombectomy System
NCT05928221
Recruiting
A post-market study of the QuickClear Mechanical Thrombectomy system used for the removal of acute Deep Vein Thrombosis (DVT) from the deep veins of legs in the setting of an office interventional suite.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
08/23/2024
Locations: Vascular Care Connecticut, Darien, Connecticut
Conditions: Acute Deep Venous Thrombosis of Ileofemoral Vein
Register for Updates
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200
Recruiting
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: GSK Investigational Site, New Haven, Connecticut
Conditions: Colonic Neoplasms, Neoplasms, Colon
Register for Updates
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
NCT02559778
Recruiting
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
08/21/2024
Locations: Connecticut Children's Hospital, Hartford, Connecticut
Conditions: Neuroblastoma
Register for Updates
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
NCT05011383
Recruiting
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/19/2024
Locations: VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut
Conditions: Metastatic Prostate Cancer
Register for Updates
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
NCT03832361
Recruiting
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
Gender:
FEMALE
Ages:
Between 18 years and 100 years
Trial Updated:
08/17/2024
Locations: Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut
Conditions: Endometrial Cancer
Register for Updates
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
NCT06385236
Recruiting
In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples. By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change trea... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/16/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Moderate to Severe Asthma
Register for Updates